Astec Lifesciences’ board has approved the proposal to raise funds through issuance of Non-Convertible Debentures (NCD) for expansion and development of business operations of the Company and meeting the short term and long-term financial requirements of the Company, including but not limited to, expenditure proposed to be incurred for improving the facilities being provided in its set-up and / or meeting the working capital requirements, for an amount upto Rs 50 crore. The Board of Directors of the Company, at its Meeting held on January 30, 2023 has approved the same.
Astec Lifesciences manufactures a wide range of agrochemicals and pharmaceutical intermediates.
| Company Name | CMP |
|---|---|
| UPL | 665.00 |
| PI Industries | 3144.45 |
| Bayer CropScience | 4900.45 |
| Sharda Cropchem | 1109.70 |
| Sumitomo Chemical | 441.95 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: